✨ Onyx Summary enGene priced its underwritten public offering of 12.6 million common shares and 2.7 million pre-funded warrants, raising approximately $130 million in gross proceeds, with a 30-day overallotment option available to underwriters. The financing, conducted under the company’s effective shelf registration, is expected to close on
✨ Onyx Summary Guardant Health launched the 34-member Single Namespace Working Group to establish an open standard for exabyte-scale data interoperability, creating a unified framework that links globally distributed data into a single namespace. The consortium’s transition to OASIS positions the standard for broad adoption, aiming to streamline data access
✨ Onyx Summary Legend Biotech reported third-quarter results highlighted by continued revenue growth for CARVYKTI, strengthened by updated survival data, expanded commercial manufacturing in Europe, and progress across its global clinical programs. The company ended the quarter with approximately $1.0 billion in cash and reduced its net loss year over
✨ Onyx Summary enGene initiated an underwritten public offering of its common shares, with all shares offered by the company and an additional 15% overallotment option available to underwriters, subject to market conditions. The offering will be conducted under enGene’s effective shelf registration and supports ongoing advancement of its non-viral
✨ Onyx Summary Kyverna Therapeutics reported third-quarter progress across its neuroimmunology CAR T franchise, including positive interim Phase 2 data in generalized myasthenia gravis, advancement of its registrational trials in stiff person syndrome and gMG, and continued expansion into additional autoimmune indications, supported by upcoming milestones such as an early-2026 SPS
✨ Onyx Summary Neochromosome and GlobalBio introduced an integrated platform that combines ALTHEA antibody libraries with the neoSwitch yeast system to enable rapid, in-house biologics discovery with streamlined transitions from display to secretion. The collaboration reduces the cost and duration of antibody screening by eliminating traditional library construction steps and providing
✨ Onyx Summary enGene reported additional preliminary Phase 2 LEGEND data for detalimogene voraplasmid in high-risk BCG-unresponsive NMIBC, showing a 63% complete response rate at any time and improved 6-month CR rates under an amended protocol, alongside a favorable safety profile across 125 patients. The company has aligned its primary endpoint
✨ Onyx Summary Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, with live and archived access available through the company’s investor events page. THE WOODLANDS, TEXAS, NOV. 11, 2025 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced
✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 1:00 p.m. GMT. A live and archived webcast of the presentation will be available on the company’s investor relations website for 90 days.
✨ Onyx Summary SpyGlass Pharma reported positive data from two clinical trials of its Bimatoprost Drug Pad-IOL System (BIM-IOL System) for patients with open-angle glaucoma or ocular hypertension, showing sustained intraocular pressure reduction and elimination of topical drops. The 36-month FIH study and interim Phase I/II results demonstrated strong safety,
✨ Onyx Summary enGene Holdings announced it will host a conference call and webcast on November 11, 2025, to present new preliminary data from the pivotal cohort of its ongoing LEGEND trial evaluating detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer. Supporting materials, including a slide deck and replay, will be
✨ Onyx Summary Perspective Therapeutics reported a third-quarter 2025 net loss of $26.0 million and ended the period with $174 million in cash, providing funding into late 2026. The company advanced multiple clinical programs, including strong interim safety and efficacy data for [212Pb]VMT-α-NET in neuroendocrine tumors, ongoing studies of
✨ Onyx Summary Lexicon Pharmaceuticals announced new data from the SOTA P CARDIA trial presented at AHA 2025 showing that sotagliflozin significantly improved cardiac structure, diastolic function, exercise capacity, and quality of life in heart failure patients with preserved ejection fraction and without diabetes. The findings, led by Mount Sinai’s
✨ Onyx Summary Guardant Health announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 19 and the Piper Sandler 37th Annual Healthcare Conference in New York on December 2. Live and archived webcasts of both fireside chats will be available on the company’
✨ Onyx Summary Seer announced that new data powered by its Proteograph Product Suite will be featured at the 2025 HUPO World Congress, highlighting how deep, scalable proteomics is advancing research in cardiovascular, oncology, and aging biology. With over a dozen scientific presentations and two invited talks, the company’s participation
✨ Onyx Summary Lexicon Pharmaceuticals reported third-quarter 2025 revenue of $14.2 million, driven by $13.2 million in licensing revenue from its Novo Nordisk agreement and $1.0 million from U.S. sales of INPEFA, narrowing its net loss to $12.8 million from $64.8 million a year earlier.
